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In the early 1990s, WHO declared TB a global 
emergency [1]. Since that time after introduction 
of DOTS strategy and National TB Programs, 
the reduction of global incidence rate (2002), as 
well as of total number of TB cases (2006) were 
recorded. However, in 2012, about 8.6 million 
cases were established, of which only two third 
were registered. It means that 3 million cases were 
missed and untreated. According to the new-post 
2015 Global TB Strategy, TB epidemic will end 
by 2035, when the incidence rate decrease to 
< 10 TB cases/100 000 population.
Can IGRAs be helpful to achieve this goal?
Approximately ten years ago, alternative to 
TST – IFN-gamma release assays (IGRAs) were 
introduced for diagnosis of latent TB infection 
(LTBI). Two commercial IGRA tests are currently 
available: QuantiFERON-TB GOLD IN Tube (QFN-
GIT) (Cellestis, Carnegie, Australia) and T-SPOT.
TB (Oxford, Immunotec, Abingdon, UK). They are 
based on the detection of IFN-gamma secreted by 
T cells stimulated by three antigens specific for 
M. tuberculosis: early secretory antigenic target 
(ESAT)-6, culture filtrate protein (CFP)-10 en-
coded in region of difference (RD)-1 and TB 7.7 
encoded in RD 11. The advantage of IGRA tests 
over the tuberculin skin test (TST) is the lack of 
cross-reactivity with M. bovis BCG strains and 
with the majority of nontuberculous mycobac-
teria (NTM). Moreover, IFN-gamma assays, as in 
vitro tests, may be performed repeatedly without 
booster effect.
Although there is no gold standard for di-
agnosis of LTBI, IGRAs identify this population 
better, compared to TST. But in many areas in 
Europe, including Poland, identification of sub-
jects with LTBI relies on a much cheaper and 
easier to perform (without the requirement of 
special laboratory equipment) TST. The analysis 
of four studies assessing IGRAs for the diagnosis 
of LTBI revealed the pooled specificity at 98% 
for T-SPOT.TB and at 100% for QFN-GIT in low 
risk population, compared to 89% for TST [2]. 
Moreover, negative predictive value (NPV) for 
progression to active disease among 1,442 healthy 
persons scored negative by QFN-GIT was 99.8% 
in 2 yrs follow-up and 97.8% for T-SPOT.TB 
(182 individuals). In the light of the above data, 
the likelihood of false negative results, although 
probable, is really low.
As one third of global population is infected 
with Mycobacterium tuberculosis, it means that 
200 million of people will develop active TB 
during their life. Can IGRAs be helpful in iden-
tifying subjects for preventive treatment? Data 
from different studies including HIV-positive and 
HIV-negative patients demonstrated that though 
IGRAs may better predict progression to active 
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disease than TST (positive predictive value — 
PPV 14% and 3%, respectively), still more than 
85% of those with positive IGRAs did not develop 
active TB [2].
For case detection and curative treatment 
remain the cornerstone of TB control, during the 
last decade, many studies have been conducted 
to assess the clinical utility of IGRAs in diagno-
sis of active TB, especially in smear and culture 
negative patients. However, sensitivity of IGRAs 
varies from 50−65%, with a specificity of about 
80% depending on epidemiological background 
(low or high burden countries), age or immune 
conditions [3, 4]. Meta-analysis revealed that 
the pooled sensitivity of IGRAs was 80% for all 
spectrum of TB cases (smear positive, culture 
positive and culture negative) and the pooled 
specificity was 79%. Although the values were 
higher than those for TST (the pooled sensitivity 
and specificity were 65% and 75%, respectively 
[5]), but still not high enough to use these tests as 
rule out assays for active TB. Nevertheless, quite 
different to QFN-GIT, T-SPOT.TB performed on 
extrasanguinous samples such as pleural fluid, 
bronchoalveolar lavage fluid (BALF) reached 
high pooled sensitivity (88%) and high pooled 
specificity (82%) [5]. If these data are confirmed 
in larger studies, for the first time this IFN-gamma 
assay can be used as immunodiagnostic test for 
active TB.
Special consideration should be paid to 
immunocompromised patients: HIV-positive, 
those with renal failure, diabetes or on immu-
nosuppressive drugs. It is well-known that HIV 
co-infection increases the risk of active TB by 
reactivation of latent infection or by favouring 
the progression of recently acquired infection 
towards active disease. Although it might be ex-
pected that IGRAs in HIV-positive population are 
less affected by immunosuppression than TST, it 
is not so evident. Meta-analysis data from the high 
and low-burden countries revealed that QFN-GIT 
sensitivity for active TB range between 61% and 
68%, and between 65% and 72% for T-SPOT.TB 
[6]. But when QFN-GIT and TST were compared, 
the pooled sensitivity was similar [6]. However, 
like in immunocompetent population, the IGRAs 
should not be used for diagnosis of active TB, as 
one third of patients could be missed. Neither 
there is enough evident data for replacement 
of TST with IGRAs for identifying HIV-positive 
subjects with LTBI.
Surprisingly, the results of the studies assess-
ing the impact of immunosuppression on IGRAs 
are inconclusive. Some studies indicated lower 
sensitivity of QFN-GIT with CD4 bellow 200 cells/ 
/mm3 [7], while the others did not find any dif-
ferences [8] or even reported higher sensitivity in 
patients with CD4 T lymphocytes below 200 cells/ 
/mm3 (T-SPOT.TB ) [9]. Also Gooovaerts et al., 
who examined IFN-gamma responses to ESAT-6 
and CFP-10, did not find any differences between 
those with TB-associated immune reconstitution 
inflammatory syndrome (TB-IRIS) and non-IRIS 
controls [10]. 
Taking into account the results of recently 
published studies and meta-analysis, WHO expert 
panel advised against using IGRAs for diagnosing 
active TB irrespective of HIV status [11]. With 
no doubt, currently used IGRAs can not replace 
bacteriological methods or NAAT (nucleic acid 
amplification test).
Not typical immunosuppression, but a kind 
of systemic anergy is present in patients with 
sarcoidosis. In this issue of “Pneumonologia i 
Allergologia Polska”, Kempisty et al. [12] con-
tribute to our knowledge of IGRAs spectrum in 
such patients. In their study of 151 patients, BCG 
vaccinated in the past with confirmed sarcoidosis, 
QFN-GIT was performed in all of them, while 
T-SPOT.TB only in a subgroup of subjects. They 
represented all stages of sarcoidosis with differ-
ent activity. It is worth noting that it is the first 
study in which both IGRA tests were performed 
in patients with sarcoidosis. In such population 
two aspects should be taken into consideration: 
decreased systemic immune reactions and the 
common mycobacterial antigens. Due to different 
populations of Treg cells: CD4+CD25+FOXP3+, 
CD4+CD39+ peripheral immune reactions, like 
TST are inhibited, while the local ones are en-
hanced (so-called immune paradox). However, 
the positive results of QFN-GIT were similar 
to that reported by the others, and reflected TB 
prevalence in different settings: low in Denmark 
[13] and high in India [14]. Also in our own study 
conducted by Piotrowski et al (under review), 
the frequency of positive QFN-GIT did not differ 
from that in age-matched control group with 
low exposure to M. tuberculosis infection. The 
activity of the disease was not associated with 
IGRAs results. Of note, authors did not demon-
strate intermediate IGRAs results, which affected 
mainly QFN-GIT and to a lesser extent T-SPOT.
TB in immunocompromised populations [15].
Secondly, it has been suspected for more 
than 100 years, that mycobacteria or more likely 
their products elicit immune responses leading 
to sarcoidosis. Mycobacterial proteins and DNA 
have been found within sarcoidosis granulomas, 
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as well as adoptive immune response to these 
targets were widely demonstrated [16−18]. Re-
cently, ESAT-6 – one of the three proteins used 
in IGRAs has been detected in sarcoidosis tissue. 
Moreover, in half of the patients with sarcoidosis, 
the response of CD4 and CD8 T cells from BALF 
to ESAT-6 was noticed [16]. However, Kempisty 
et al. [12] found comparable IGRAs results for 
that of local population. So, from the diagnostic 
point of view, IFN-gamma assays, quite opposite 
to TST, seem to be reliable methods for detection 
of LTBI in sarcoidosis patients as well.
 In conclusion, the indication for IGRA 
tests is still the diagnosis of LTBI, especially in 
BCG-vaccinated populations. These tests can not 
differentiate LTBI from active disease or those 
who would benefit from preventive treatment. 
As ESAT-6 is secreted in all stages of latency and 
in active TB, new immune-based tests with new 
infection-phases specific antigens are needed. 
High NPV of QFN-GIT shows the opportunity to 
use this test to exclude TB infection or even active 
disease in some clinical situations. 
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